CDK17

Summary

CDK17 (cyclin dependent kinase 17, HGNC:8750) is a protein-coding gene on chromosome 12q23.1, encoding Cyclin-dependent kinase 17 (Q00537). May play a role in terminally differentiated neurons.

The protein encoded by this gene belongs to the cdc2/cdkx subfamily of the ser/thr family of protein kinases. It has similarity to a rat protein that is thought to play a role in terminally differentiated neurons. Alternatively spliced transcript variants encoding different isoforms have been found.

Source: NCBI Gene 5128 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 68 total
• Druggable target: yes — 33 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_002595

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:8750
Approved symbol	CDK17
Name	cyclin dependent kinase 17
Location	12q23.1
Locus type	gene with protein product
Status	Approved
Aliases	PCTAIRE2
Ensembl gene	ENSG00000059758
Ensembl biotype	protein_coding
OMIM	603440
Entrez	5128

Gene structure

Transcript identifiers

Ensembl transcripts: 25 — 20 protein_coding, 3 retained_intron, 2 protein_coding_CDS_not_defined

ENST00000261211, ENST00000542666, ENST00000543119, ENST00000548422, ENST00000548734, ENST00000549899, ENST00000550971, ENST00000551484, ENST00000551816, ENST00000552262, ENST00000552496, ENST00000553042, ENST00000859518, ENST00000859519, ENST00000859520, ENST00000859521, ENST00000859522, ENST00000964177, ENST00000964178, ENST00000964179, ENST00000964180, ENST00000964181, ENST00000964182, ENST00000964183, ENST00000964184

RefSeq mRNA: 2 — MANE Select: NM_002595 NM_001170464, NM_002595

CCDS: CCDS53819, CCDS9061

Canonical transcript exons

ENST00000261211 — 17 exons

Exon	Start	End
ENSE00000817991	96311052	96311177
ENSE00000994210	96313321	96313454
ENSE00001275553	96280808	96280885
ENSE00001275561	96282509	96282599
ENSE00001275567	96283603	96283645
ENSE00001276071	96278261	96280279
ENSE00001345590	96399986	96400439
ENSE00003496344	96298869	96298983
ENSE00003497295	96300304	96300360
ENSE00003505363	96294999	96295122
ENSE00003526008	96286664	96286761
ENSE00003549841	96286043	96286148
ENSE00003605664	96297627	96297721
ENSE00003637695	96323948	96324112
ENSE00003682723	96297270	96297332
ENSE00003688747	96334719	96334865
ENSE00003693586	96289167	96289287

Expression profiles

Bgee: expression breadth ubiquitous, 295 present calls, max score 97.41.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 31.7529 / max 440.6746, expressed in 1819 samples.

FANTOM5 promoters (12 alternative TSS)

Promoter ID	TPM avg	Samples expressed
132798	22.9953	1816
132800	2.9035	1547
132797	1.6686	514
132799	1.5621	951
132796	0.8344	310
132780	0.5431	215
132791	0.4174	212
132793	0.2545	104
132794	0.2165	92
132792	0.2077	89

Top tissues by expression

300 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
corpus callosum	UBERON:0002336	97.41	gold quality
CA1 field of hippocampus	UBERON:0003881	97.34	gold quality
Brodmann (1909) area 23	UBERON:0013554	97.28	gold quality
lateral globus pallidus	UBERON:0002476	96.77	gold quality
calcaneal tendon	UBERON:0003701	96.32	gold quality
visceral pleura	UBERON:0002401	96.00	gold quality
postcentral gyrus	UBERON:0002581	95.73	gold quality
vena cava	UBERON:0004087	95.73	gold quality
superior frontal gyrus	UBERON:0002661	95.71	gold quality
middle temporal gyrus	UBERON:0002771	95.64	gold quality
entorhinal cortex	UBERON:0002728	95.57	gold quality
parietal lobe	UBERON:0001872	95.47	gold quality
orbitofrontal cortex	UBERON:0004167	95.32	gold quality
substantia nigra pars reticulata	UBERON:0001966	95.24	gold quality
germinal epithelium of ovary	UBERON:0001304	95.01	gold quality
subthalamic nucleus	UBERON:0001906	94.93	gold quality
globus pallidus	UBERON:0001875	94.89	gold quality
tibia	UBERON:0000979	94.73	gold quality
substantia nigra pars compacta	UBERON:0001965	94.50	gold quality
colonic epithelium	UBERON:0000397	94.47	gold quality
medial globus pallidus	UBERON:0002477	94.40	gold quality
occipital lobe	UBERON:0002021	94.38	gold quality
choroid plexus epithelium	UBERON:0003911	94.37	gold quality
nucleus accumbens	UBERON:0001882	94.28	gold quality
pleura	UBERON:0000977	94.27	gold quality
primary visual cortex	UBERON:0002436	94.26	gold quality
inferior olivary complex	UBERON:0002127	94.08	gold quality
Brodmann (1909) area 46	UBERON:0006483	94.08	gold quality
pericardium	UBERON:0002407	94.07	gold quality
secondary oocyte	CL:0000655	93.97	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.94

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

207 targeting CDK17, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-3646	100.00	73.56	5283
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-3064-3P	100.00	70.09	1254
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-223-3P	99.99	70.14	1140
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-433-3P	99.98	69.37	1203
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595

Literature-anchored findings (GeneRIF, showing 3)

• Increased levels of PCTAIRE2 is associated with Alzheimer’s disease. (PMID:26885753)
• CircCDK17 knockdown inhibits tumor progression and cell glycolysis by downregulaing YWHAZ expression through sponging miR-1294 in cervical cancer. (PMID:35168653)
• CircCDK17 promotes the proliferation and metastasis of ovarian cancer cells by sponging miR-22-3p to regulate CD147 expression. (PMID:37952105)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	cdk17	ENSDARG00000079470
mus_musculus	Cdk17	ENSMUSG00000020015
rattus_norvegicus	Cdk17	ENSRNOG00000004148

Paralogs (26): CDKL3 (ENSG00000006837), CDKL5 (ENSG00000008086), CDK11A (ENSG00000008128), CDK14 (ENSG00000058091), CDK13 (ENSG00000065883), CDKL1 (ENSG00000100490), CDK16 (ENSG00000102225), CDK6 (ENSG00000105810), PRP4K (ENSG00000112739), CDK18 (ENSG00000117266), CDK2 (ENSG00000123374), CDK8 (ENSG00000132964), CDK7 (ENSG00000134058), CDK4 (ENSG00000135446), CDK9 (ENSG00000136807), CDK15 (ENSG00000138395), CDKL2 (ENSG00000138769), CDK19 (ENSG00000155111), CDK20 (ENSG00000156345), CDK5 (ENSG00000164885), CDK12 (ENSG00000167258), CDK1 (ENSG00000170312), CDK10 (ENSG00000185324), CDKL4 (ENSG00000205111), CDK11B (ENSG00000248333), CDK3 (ENSG00000250506)

Protein

Protein identifiers

Cyclin-dependent kinase 17 — Q00537 (reviewed: Q00537)

Alternative names: Cell division protein kinase 17, PCTAIRE-motif protein kinase 2, Serine/threonine-protein kinase PCTAIRE-2

All UniProt accessions (6): Q00537, F5H6Z0, F8VQZ9, F8VUX2, F8VZY6, F8W1S5

UniProt curated annotations — full annotation on UniProt →

Function. May play a role in terminally differentiated neurons. Has a Ser/Thr-phosphorylating activity for histone H1.

Subunit / interactions. Found in a complex containing CABLES1, CDK16 and TDRD7. Interacts with TDRD7.

Similarity. Belongs to the protein kinase superfamily. CMGC Ser/Thr protein kinase family. CDC2/CDKX subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
Q00537-1	1	yes
Q00537-2	2

RefSeq proteins (2): NP_001163935, NP_002586* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000719	Prot_kinase_dom	Domain
IPR008271	Ser/Thr_kinase_AS	Active_site
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR017441	Protein_kinase_ATP_BS	Binding_site
IPR050108	CDK	Family

Pfam: PF00069

Enzyme classification (BRENDA):

• EC 2.7.11.22 — cyclin-dependent kinase (BRENDA: 49 organisms, 441 substrates, 555 inhibitors, 8 Km, 4 kcat entries)

Substrate kinetics (BRENDA)

4 substrates with measured Km, best-characterized 4. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ADAQHATPPKKKRKVEDPKDF	0.046–0.521	2
ATP	0.0052–0.017	2
FIN1	0.003	1
PKTPKKAKKL	0.0029	1

Catalyzed reactions (Rhea), 2 shown:

• L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H(+) (RHEA:17989)
• L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H(+) (RHEA:46608)

UniProt features (23 total): modified residue 8, region of interest 3, sequence conflict 3, compositionally biased region 2, binding site 2, chain 1, domain 1, splice variant 1, sequence variant 1, active site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q00537-F1	70.51	0.43

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 313 (proton acceptor)

Ligand- & substrate-binding residues (2): 198–206; 221

Post-translational modifications (8): 9, 80, 92, 105, 137, 146, 165, 180

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 302 (showing top): MYAATNNNNNNNGGC_UNKNOWN, TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, GOBP_CELL_CYCLE_PHASE_TRANSITION, ACTGCAG_MIR173P, GGGTGGRR_PAX4_03, XU_HGF_SIGNALING_NOT_VIA_AKT1_48HR_UP, ONKEN_UVEAL_MELANOMA_UP, GOBP_REGULATION_OF_CELL_CYCLE, DACOSTA_UV_RESPONSE_VIA_ERCC3_COMMON_DN, DEBIASI_APOPTOSIS_BY_REOVIRUS_INFECTION_UP, AACTTT_UNKNOWN, BENPORATH_NOS_TARGETS, ATCATGA_MIR433, P300_01, ACTTTAT_MIR1425P

GO Biological Process (2): protein phosphorylation (GO:0006468), regulation of cell cycle phase transition (GO:1901987)

GO Molecular Function (9): protein kinase activity (GO:0004672), cyclin-dependent protein serine/threonine kinase activity (GO:0004693), ATP binding (GO:0005524), protein serine kinase activity (GO:0106310), nucleotide binding (GO:0000166), protein serine/threonine kinase activity (GO:0004674), protein binding (GO:0005515), kinase activity (GO:0016301), transferase activity (GO:0016740)

GO Cellular Component (2): nucleus (GO:0005634), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein kinase activity	2
phosphorylation	1
protein modification process	1
regulation of cell cycle process	1
cell cycle phase transition	1
kinase activity	1
phosphotransferase activity, alcohol group as acceptor	1
catalytic activity, acting on a protein	1
protein serine/threonine kinase activity	1
cyclin-dependent protein kinase activity	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
transferase activity, transferring phosphorus-containing groups	1
catalytic activity	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

3217 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CDK17	TDRD7	Q8NHU6	910
CDK17	CABLES1	Q8TDN4	882
CDK17	CCDC180	Q9P1Z9	829
CDK17	CCNA2	P20248	565
CDK17	CCNY	Q8ND76	549
CDK17	CCNA1	P78396	543
CDK17	CCNL2	Q96S94	521
CDK17	CCNC	P24863	517
CDK17	SCGN	O76038	460
CDK17	CCND3	P30281	455
CDK17	SUSD4	Q5VX71	429
CDK17	CCNE2	O96020	416
CDK17	MGAT4C	Q9UBM8	389
CDK17	SIK3	Q9Y2K2	386
CDK17	CDK10	Q15131	385

IntAct

91 interactions, top by confidence:

A	B	Type	Score
S100B	S100A4	psi-mi:“MI:0914”(association)	0.870
CDK2	CCNB2	psi-mi:“MI:0914”(association)	0.860
YWHAG	CDK17	psi-mi:“MI:0915”(physical association)	0.860
CDK1	CCNB2	psi-mi:“MI:0914”(association)	0.840
YWHAB	PIK3C2A	psi-mi:“MI:0914”(association)	0.800
CDK17	YWHAZ	psi-mi:“MI:0914”(association)	0.800
CDK17	YWHAZ	psi-mi:“MI:0915”(physical association)	0.800
CDK14	CDKN1A	psi-mi:“MI:0914”(association)	0.770
CCNB2	CDKN1B	psi-mi:“MI:0914”(association)	0.670
YWHAG	BLTP3B	psi-mi:“MI:0914”(association)	0.640
PPP2R3A	WTIP	psi-mi:“MI:0914”(association)	0.640
CDK17	YWHAE	psi-mi:“MI:0915”(physical association)	0.620
CDK17	CDK16	psi-mi:“MI:0915”(physical association)	0.620
CDK16	CDK17	psi-mi:“MI:0914”(association)	0.620
YWHAH	PLEKHG3	psi-mi:“MI:0914”(association)	0.610
YWHAB	BLTP3B	psi-mi:“MI:0914”(association)	0.610
TDRD7	TACC1	psi-mi:“MI:0914”(association)	0.580
YWHAE	PIK3C2A	psi-mi:“MI:0914”(association)	0.570
YWHAH	BLTP3B	psi-mi:“MI:0914”(association)	0.570
YWHAZ	PIK3C2A	psi-mi:“MI:0914”(association)	0.570
CDK17	DPY30	psi-mi:“MI:0915”(physical association)	0.560
CDKN2B	CDK17	psi-mi:“MI:0915”(physical association)	0.560
BICDL2	CDK17	psi-mi:“MI:0915”(physical association)	0.560
YWHAG	SHTN1	psi-mi:“MI:0914”(association)	0.560
MANSC1	KLRG2	psi-mi:“MI:0914”(association)	0.530
CDK16	CSNK2A2	psi-mi:“MI:0914”(association)	0.530
YWHAQ	IGLC7	psi-mi:“MI:0914”(association)	0.530

BioGRID (105): CDK17 (Affinity Capture-MS), CDK17 (Affinity Capture-MS), CDK17 (Affinity Capture-MS), PPP2R3A (Affinity Capture-MS), TDRD7 (Affinity Capture-MS), SUGP1 (Affinity Capture-MS), DHPS (Affinity Capture-MS), PPP2R5E (Affinity Capture-MS), C12orf43 (Affinity Capture-MS), FEM1A (Affinity Capture-MS), CDK17 (Reconstituted Complex), CDK17 (Affinity Capture-MS), CDK17 (Affinity Capture-MS), CDK17 (Affinity Capture-MS), PPP2R3A (Affinity Capture-MS)

ESM2 similar proteins: A1CL96, A1D624, A2QU77, A2X0M1, A2Y4B6, A3LUB9, A4IIW7, A4QXX4, B0VXE8, B0VXL7, B6A7Q3, C0RW22, O13958, O35495, O35831, O35832, O44514, O94921, P0CS76, P0CS77, P29620, Q00536, Q00537, Q04735, Q04899, Q07002, Q0CQK1, Q0E459, Q0TWJ7, Q11179, Q1EBK0, Q1RLU9, Q2GYV9, Q2UC58, Q336M2, Q39010, Q4FCZ5, Q4WYR6, Q5BAE1, Q5RD01

Diamond homologs: A4IIW7, A8XA58, B0VXE8, B0VXL7, B6A7Q3, C0RW22, G5ECH7, O35495, O35831, O35832, O55076, O61847, O74456, O94921, O96821, P00546, P04551, P06493, P11440, P13863, P17157, P23111, P23437, P23572, P23573, P24033, P24100, P24923, P24941, P25859, P29618, P29619, P34112, P34117, P35567, P38973, P39951, P43063, P43450, P48609

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 85 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	8	89.6×	3e-12
Activation of BAD and translocation to mitochondria	7	88.8×	7e-11
SARS-CoV-1 targets host intracellular signalling and regulatory pathways	7	78.4×	2e-10
Activation of BH3-only proteins	7	57.9×	1e-09
TP53 Regulates Transcription of Cell Cycle Genes	5	45.3×	2e-06
FOXO-mediated transcription	7	39.2×	2e-08
RHO GTPases activate PKNs	7	37.0×	3e-08
Intrinsic Pathway for Apoptosis	7	34.2×	5e-08

GO biological processes:

GO term	Partners	Fold	FDR
protein targeting	5	23.8×	1e-03
cellular senescence	5	19.2×	1e-03
G1/S transition of mitotic cell cycle	5	13.0×	4e-03
intracellular protein localization	7	9.5×	1e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

68 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	48
Likely benign	0
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

2803 predictions. Top by Δscore:

Variant	Effect	Δscore
12:96280883:CAC:C	acceptor_gain	1.0000
12:96280885:CCT:C	acceptor_loss	1.0000
12:96280886:CT:C	acceptor_loss	1.0000
12:96280887:T:A	acceptor_loss	1.0000
12:96282503:TCTTA:T	donor_loss	1.0000
12:96282505:TTA:T	donor_loss	1.0000
12:96282506:TA:T	donor_loss	1.0000
12:96282507:A:AC	donor_gain	1.0000
12:96282508:C:CA	donor_gain	1.0000
12:96282508:CT:C	donor_gain	1.0000
12:96282508:CTTT:C	donor_gain	1.0000
12:96282511:T:A	donor_gain	1.0000
12:96282595:TCATA:T	acceptor_gain	1.0000
12:96282596:CATA:C	acceptor_gain	1.0000
12:96282596:CATAC:C	acceptor_gain	1.0000
12:96282597:ATA:A	acceptor_gain	1.0000
12:96282598:TA:T	acceptor_gain	1.0000
12:96282598:TACT:T	acceptor_loss	1.0000
12:96282600:C:CA	acceptor_loss	1.0000
12:96282600:C:CC	acceptor_gain	1.0000
12:96282601:T:G	acceptor_loss	1.0000
12:96282602:G:C	acceptor_gain	1.0000
12:96282602:G:GC	acceptor_gain	1.0000
12:96283598:CTTA:C	donor_loss	1.0000
12:96283599:TTA:T	donor_loss	1.0000
12:96283600:TA:T	donor_loss	1.0000
12:96283641:CTAAC:C	acceptor_gain	1.0000
12:96283642:TAAC:T	acceptor_gain	1.0000
12:96283646:C:CC	acceptor_gain	1.0000
12:96283646:CTA:C	acceptor_loss	1.0000

AlphaMissense

3413 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:96282582:C:A	R461S	1.000
12:96282582:C:G	R461S	1.000
12:96286687:A:G	L398P	1.000
12:96286708:C:T	G391E	1.000
12:96286709:C:G	G391R	1.000
12:96286709:C:T	G391R	1.000
12:96286735:A:C	M382R	1.000
12:96286737:T:A	E381D	1.000
12:96286737:T:G	E381D	1.000
12:96286738:T:A	E381V	1.000
12:96286739:C:T	E381K	1.000
12:96286749:G:C	C377W	1.000
12:96286750:C:T	C377Y	1.000
12:96286751:A:G	C377R	1.000
12:96286753:C:T	G376D	1.000
12:96286754:C:G	G376R	1.000
12:96286760:C:G	G374R	1.000
12:96289168:A:G	W373R	1.000
12:96289168:A:T	W373R	1.000
12:96289173:T:A	D371V	1.000
12:96289173:T:C	D371G	1.000
12:96289173:T:G	D371A	1.000
12:96289174:C:A	D371Y	1.000
12:96289174:C:G	D371H	1.000
12:96289188:T:C	Y366C	1.000
12:96289189:A:G	Y366H	1.000
12:96289206:A:G	L360P	1.000
12:96289206:A:T	L360H	1.000
12:96289215:G:T	P357H	1.000
12:96289218:G:T	P356Q	1.000

dbSNP variants (sampled 300 via entrez): RS1000033130 (12:96305081 C>A,G,T), RS1000049339 (12:96347182 G>C), RS1000051447 (12:96328351 G>A), RS1000081841 (12:96328673 C>G), RS1000121856 (12:96369146 T>C), RS1000122384 (12:96345766 A>G), RS1000153846 (12:96351136 C>G), RS1000185986 (12:96304291 C>T), RS1000216718 (12:96391500 A>G), RS1000256340 (12:96298577 AGTTT>A), RS1000317595 (12:96377081 T>C), RS1000343945 (12:96310247 C>A,G), RS1000346470 (12:96310855 T>C), RS1000382644 (12:96322161 G>A), RS1000410734 (12:96397175 T>C)

Disease associations

OMIM: gene MIM:603440 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): breast ductal adenocarcinoma (MONDO:0005590)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST001414_1	Phospholipid levels (plasma)	3.000000e-08
GCST002932_5	Manganese levels	6.000000e-06
GCST006630_36	Diastolic blood pressure	4.000000e-11

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0006336	diastolic blood pressure

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D018270	Carcinoma, Ductal, Breast	C04.557.470.200.025.232.500; C04.557.470.615.132.500; C04.588.180.390; C17.800.090.500.390

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (4): CHEMBL3559691 (PROTEIN FAMILY), CHEMBL4523636 (PROTEIN COMPLEX), CHEMBL4523637 (PROTEIN COMPLEX), CHEMBL5790 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

33 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 273,526 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1078178	MOMELOTINIB	4	3,481
CHEMBL1171837	PONATINIB	4	8,955
CHEMBL1287853	FEDRATINIB	4	3,554
CHEMBL1336	SORAFENIB	4	86,060
CHEMBL189963	PALBOCICLIB	4	13,102
CHEMBL1946170	REGORAFENIB	4	12,678
CHEMBL2028663	DABRAFENIB	4	12,430
CHEMBL502835	NINTEDANIB	4	8,545
CHEMBL535	SUNITINIB	4	79,020
CHEMBL576982	QUIZARTINIB	4	4,432
CHEMBL2103840	DINACICLIB	3	2,257
CHEMBL428690	ALVOCIDIB	3	27,781
CHEMBL522892	DOVITINIB	3	4,944
CHEMBL603469	LESTAURTINIB	3
CHEMBL1276127	INDIRUBIN	2	181
CHEMBL5199065	ISTISOCICLIB	2	21
CHEMBL1230609	FORETINIB	2	3,096
CHEMBL1738757	REBASTINIB	2	1,478
CHEMBL3039513	DECERNOTINIB	2	1,418
CHEMBL384304	RG-547	2	93
CHEMBL3991932	PEXMETINIB	2
CHEMBL445813	AT-7519	2
CHEMBL475251	R-406	2
CHEMBL495727	AT-9283	2
CHEMBL564829	MILCICLIB	2
CHEMBL572878	TOZASERTIB	2
CHEMBL1084546	PF-00562271	1
CHEMBL1908397	KW-2449	1
CHEMBL296468	BMS-387032	1
CHEMBL3128043	PF-03758309	1

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — TAIRE subfamily

Binding affinities (BindingDB)

8 measured of 8 human assays (8 total across all organisms); most potent 8 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
Staurosporine	KD	1.7 nM
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide	KD	370 nM
(3Z)-4-amino-5-fluoro-3-[5-(4-methylpiperazino)-1,3-dihydrobenzimidazol-2-ylidene]carbostyril	KD	520 nM
1-[4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[[6-(methylamino)-4-pyrimidinyl]oxy]phenyl]urea	KD	1400 nM
BMS-387072	KD	1800 nM
1-Acyl-1H-[1,2,4]triazole-3,5-diamine Analogue 3b	KD	3100 nM
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide	KD	3500 nM
2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S)-3-hydroxy-1-methyl-4-piperidinyl]-1-benzopyran-4-one	KD	5300 nM

ChEMBL bioactivities

62 potent at pChembl≥5 of 66 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.07	Kd	0.86	nM	RG-547
9.02	Kd	0.95	nM	AT-7519
8.70	Kd	2	nM	BMS-387032
8.30	Kd	5	nM	XL-228
8.22	Kd	6	nM	ALVOCIDIB
8.15	Kd	7	nM	CYC-116
8.15	Kd	7	nM	AT-7519
8.15	Kd	7	nM	REBASTINIB
7.97	IC50	10.7	nM	STAUROSPORINE
7.89	Kd	13	nM	BMS-387032
7.86	IC50	13.8	nM	STAUROSPORINE
7.85	Kd	14	nM	PF-03758309
7.82	Kd	15	nM	AST-487
7.79	IC50	16.3	nM	STAUROSPORINE
7.44	Kd	36	nM	DABRAFENIB
7.16	Kd	69	nM	CHEMBL1082152
7.05	Kd	89	nM	PF-00562271
7.03	Kd	93	nM	NINTEDANIB
7.02	Kd	96	nM	STAUROSPORINE
6.92	Kd	120.5	nM	CHEMBL5653589
6.92	ED50	120.5	nM	CHEMBL5653589
6.86	Kd	139	nM	DECERNOTINIB
6.77	Kd	170	nM	FORETINIB
6.54	Kd	290	nM	JNJ-7706621
6.48	Kd	330	nM	R-406
6.47	Kd	335	nM	PONATINIB
6.46	Kd	350	nM	FEDRATINIB
6.40	Kd	402	nM	PEXMETINIB
6.32	Kd	480	nM	ALVOCIDIB
6.14	Kd	719	nM	REGORAFENIB
6.14	Kd	720	nM	LESTAURTINIB
6.11	Kd	778	nM	DINACICLIB
6.09	Kd	810	nM	TAE-684
6.06	Kd	880	nM	PHA-665752
6.00	IC50	1000	nM	TP-030-1
6.00	IC50	1000	nM	TP-030-2
6.00	IC50	1000	nM	TP-030n
5.94	Kd	1148	nM	AT-9283
5.93	Kd	1177	nM	MILCICLIB
5.92	Kd	1200	nM	SUNITINIB
5.90	Kd	1272	nM	PALBOCICLIB
5.86	Kd	1382	nM	MOMELOTINIB
5.82	IC50	1500	nM	CHEMBL3656841
5.80	Kd	1600	nM	SORAFENIB
5.75	Kd	1780	nM	CHEMBL4084193
5.72	Kd	1900	nM	KW-2449
5.72	Kd	1900	nM	CHEMBL379218
5.66	IC50	2200	nM	INDIRUBIN
5.54	Kd	2880	nM	SUNITINIB
5.52	Kd	3000	nM	DOVITINIB

PubChem BioAssay actives

56 with measured affinity, of 546 total; 39 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-[(2,6-dichlorobenzoyl)amino]-N-piperidin-4-yl-1H-pyrazole-5-carboxamide	624776: Binding constant for PCTK2 kinase domain	kd	0.0009	uM
[4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone	624776: Binding constant for PCTK2 kinase domain	kd	0.0009	uM
N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide	1424942: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0020	uM
4-N-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-N-[(3-propan-2-yl-1,2-oxazol-5-yl)methyl]pyrimidine-2,4-diamine	1424942: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0050	uM
2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one	1424942: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0060	uM
4-[4-[(3-tert-butyl-1-quinolin-6-ylpyrazol-5-yl)carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide	1424942: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0070	uM
4-methyl-5-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine	1424942: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0070	uM
(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one	1715415: Inhibition of human CDK17/cyclin-Y using MBP protein as substrate by [gamma-33P]-ATP assay	ic50	0.0107	uM
N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methylthieno[3,2-d]pyrimidin-4-yl)amino]-1,4-dihydropyrrolo[3,4-d]pyrazole-5-carboxamide	1424942: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0140	uM
1-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[6-(methylamino)pyrimidin-4-yl]oxyphenyl]urea	435688: Binding constant for full-length PCTK2	kd	0.0150	uM
Dabrafenib	1424942: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0360	uM
3-[3-(2,3-dihydroxypropylamino)phenyl]-4-(5-fluoro-1-methylindol-3-yl)pyrrole-2,5-dione	465268: Inhibition of PCTK2	kd	0.0690	uM
N-methyl-N-[3-[[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]methyl]-2-pyridinyl]methanesulfonamide	1424942: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0890	uM
methyl 2-hydroxy-3-[N-[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]phenyl]-C-phenylcarbonimidoyl]-1H-indole-6-carboxylate	624776: Binding constant for PCTK2 kinase domain	kd	0.0930	uM
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148046: Binding affinity to human CDK17 incubated for 45 mins by Kinobead based pull down assay	kd	0.1205	uM
(2R)-2-methyl-2-[[2-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]-N-(2,2,2-trifluoroethyl)butanamide	1424942: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.1390	uM
1-N’-[3-fluoro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide	624776: Binding constant for PCTK2 kinase domain	kd	0.1700	uM
4-[[5-amino-1-(2,6-difluorobenzoyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide	435688: Binding constant for full-length PCTK2	kd	0.2900	uM
6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one	624776: Binding constant for PCTK2 kinase domain	kd	0.3300	uM
Ponatinib	1424942: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.3350	uM
Fedratinib	624776: Binding constant for PCTK2 kinase domain	kd	0.3500	uM
1-[3-tert-butyl-1-(4-methylphenyl)pyrazol-5-yl]-3-[[5-fluoro-2-[1-(2-hydroxyethyl)indazol-5-yl]oxyphenyl]methyl]urea	1424942: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.4020	uM
regorafenib anhydrous	1424942: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.7190	uM
(15S,16S,18R)-16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaen-3-one	507663: Binding affinity to PCTK2	kd	0.7200	uM
2-[(2S)-1-[3-ethyl-7-[(1-oxidopyridin-1-ium-3-yl)methylamino]pyrazolo[1,5-a]pyrimidin-5-yl]piperidin-2-yl]ethanol	1424942: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.7780	uM
5-chloro-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine	624776: Binding constant for PCTK2 kinase domain	kd	0.8100	uM
(3Z)-5-[(2,6-dichlorophenyl)methylsulfonyl]-3-[[3,5-dimethyl-4-[(2R)-2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl]-1H-pyrrol-2-yl]methylidene]-1H-indol-2-one	624776: Binding constant for PCTK2 kinase domain	kd	0.8800	uM
1-cyclopropyl-3-[5-[6-(morpholin-4-ylmethyl)-1H-benzimidazol-2-yl]-1H-pyrazol-4-yl]urea	1424942: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	1.1480	uM
N,1,4,4-tetramethyl-8-[4-(4-methylpiperazin-1-yl)anilino]-5H-pyrazolo[4,5-h]quinazoline-3-carboxamide	1424942: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	1.1770	uM
Sunitinib	435688: Binding constant for full-length PCTK2	kd	1.2000	uM
Palbociclib	1424942: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	1.2720	uM
Momelotinib	1424942: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	1.3820	uM
4-[[[6-[5-chloro-2-[[4-[[(2R)-1-methoxypropan-2-yl]amino]cyclohexyl]amino]-4-pyridinyl]-2-pyridinyl]amino]methyl]oxane-4-carbonitrile	1921485: Inhibition of CDK17 (unknown origin) by Kinomescan method	ic50	1.5000	uM
Sorafenib	435688: Binding constant for full-length PCTK2	kd	1.6000	uM
(2S)-1-[[5-(3-methyl-2H-indazol-5-yl)-3-pyridinyl]oxy]-3-phenylpropan-2-amine	624776: Binding constant for PCTK2 kinase domain	kd	1.9000	uM
[4-[(E)-2-(1H-indazol-3-yl)ethenyl]phenyl]-piperazin-1-ylmethanone	624776: Binding constant for PCTK2 kinase domain	kd	1.9000	uM
2-(2-hydroxy-1H-indol-3-yl)indol-3-one	1378312: Inhibition of recombinant human CDK expressed in baculovirus infected sf9 cells after 10 mins by SDS-PAGE based autoradiography	ic50	2.2000	uM
4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one	435688: Binding constant for full-length PCTK2	kd	3.0000	uM
N-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide	624776: Binding constant for PCTK2 kinase domain	kd	5.6000	uM

CTD chemical–gene interactions

32 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
cobaltous chloride	decreases expression, increases expression	2
Tetrachlorodibenzodioxin	decreases expression	2
Sodium Selenite	decreases expression, increases expression	2
aristolochic acid I	decreases expression	1
FR900359	decreases phosphorylation	1
arsenite	affects binding, decreases reaction	1
sodium arsenite	increases expression	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, decreases expression	1
aflatoxin B2	decreases methylation	1
1-nitropyrene	increases expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
chromium hexavalent ion	decreases expression	1
abrine	increases expression	1
jinfukang	decreases expression	1
Leflunomide	increases expression	1
Amiodarone	increases expression	1
Benzo(a)pyrene	affects methylation	1
Caffeine	decreases phosphorylation	1
Coumestrol	affects cotreatment, decreases expression	1
Potassium Dichromate	decreases expression	1
Rotenone	decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Urethane	increases expression	1
Valproic Acid	affects expression	1
Vanadium	decreases expression	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	1
Cadmium Chloride	increases expression	1
Copper Sulfate	increases expression	1

ChEMBL screening assays

182 unique, capped per target: 182 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1064257	Binding	Inhibition of CDK in human A2780 cells assessed as reduction of RNAP2 phosphorylation at Ser2 site at 5 uM after 6 hrs by Western bloting	Design, synthesis, and evaluation of 2-methyl- and 2-amino-N-aryl-4,5-dihydrothiazolo[4,5-h]quinazolin-8-amines as ring-constrained 2-anilino-4-(thiazol-5-yl)pyrimidine cyclin-dependent kinase inhibitors. — J Med Chem

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1N0	Abcam HeLa CDK17 KO	Cancer cell line	Female
CVCL_SI26	HAP1 CDK17 (-) 1	Cancer cell line	Male
CVCL_SI27	HAP1 CDK17 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

11 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT03414970	PHASE3	ACTIVE_NOT_RECRUITING	Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
NCT00461344	PHASE2	TERMINATED	Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
NCT07499999	PHASE2	NOT_YET_RECRUITING	Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
NCT00637364	PHASE1/PHASE2	SUSPENDED	High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain
NCT02779855	PHASE1/PHASE2	COMPLETED	Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
NCT01753908	EARLY_PHASE1	COMPLETED	Broccoli Sprout Extract in Treating Patients With Breast Cancer
NCT01796041	EARLY_PHASE1	COMPLETED	Intraoperative Imaging of Breast Cancer With Indocyanine Green
NCT01208974	Not specified	ACTIVE_NOT_RECRUITING	Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction
NCT01875198	Not specified	TERMINATED	Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer
NCT03543397	Not specified	UNKNOWN	MRI in Ductal Carcinoma in Situ (DCIS)
NCT03834532	Not specified	COMPLETED	Living Well After Breast Surgery